EE03241B1 - Androstenooni derivaat 17ß-N-(2,5-bis(trifluorometüül))fenüülkarbamoüül-4-asa-5a-androst-1-een-3-oon ja selle farmatseutiliselt vastuvõetavad solvaadid - Google Patents

Androstenooni derivaat 17ß-N-(2,5-bis(trifluorometüül))fenüülkarbamoüül-4-asa-5a-androst-1-een-3-oon ja selle farmatseutiliselt vastuvõetavad solvaadid

Info

Publication number: EE03241B1
Authority: EE; Estonia
Prior art keywords: androst; phenylcarbamoyl; aza; trifluoromethyl; bis
Prior art date: 1993-09-17

Application number

EE9600130A

Other languages

English (en)

Inventor

William Batchelor Kenneth

Vernon Frye Stephen

Original Assignee

Glaxo Wellcome Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-09-17

Filing date

1994-09-16

Publication date

1999-12-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22407744&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE03241(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1994-09-16 Application filed by Glaxo Wellcome Inc. filed Critical Glaxo Wellcome Inc.

1999-12-15 Publication of EE03241B1 publication Critical patent/EE03241B1/et

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
- C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/82—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0066—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by a carbon atom forming part of an amide group
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
- C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
- C07J73/005—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
- C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
- C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
- C07C2603/14—Benz[f]indenes; Hydrogenated benz[f]indenes

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Steroid Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

EE9600130A 1993-09-17 1994-09-16 Androstenooni derivaat 17ß-N-(2,5-bis(trifluorometüül))fenüülkarbamoüül-4-asa-5a-androst-1-een-3-oon ja selle farmatseutiliselt vastuvõetavad solvaadid EE03241B1 (et)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US12328093A	1993-09-17	1993-09-17
PCT/US1994/010530 WO1995007927A1 (en)	1993-09-17	1994-09-16	Androstenone derivative

Publications (1)

Publication Number	Publication Date
EE03241B1 true EE03241B1 (et)	1999-12-15

Family

ID=22407744

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EE9600130A EE03241B1 (et)	1993-09-17	1994-09-16	Androstenooni derivaat 17ß-N-(2,5-bis(trifluorometüül))fenüülkarbamoüül-4-asa-5a-androst-1-een-3-oon ja selle farmatseutiliselt vastuvõetavad solvaadid

Country Status (41)

Country	Link
US (2)	US5565467A (et)
EP (1)	EP0719278B1 (et)
JP (1)	JP2904310B2 (et)
KR (1)	KR100364953B1 (et)
CN (1)	CN1057771C (et)
AP (1)	AP494A (et)
AT (1)	ATE162199T1 (et)
AU (1)	AU690925B2 (et)
BG (1)	BG62363B1 (et)
BR (1)	BR1100329A (et)
CA (2)	CA2170047C (et)
CY (2)	CY2219B1 (et)
CZ (1)	CZ286069B6 (et)
DE (2)	DE69407978T2 (et)
DK (1)	DK0719278T3 (et)
EE (1)	EE03241B1 (et)
ES (1)	ES2113127T3 (et)
FI (1)	FI115216B (et)
GR (1)	GR3026144T3 (et)
HK (1)	HK1004334A1 (et)
HR (1)	HRP940563B1 (et)
HU (1)	HU220060B (et)
IL (1)	IL110978A (et)
IS (1)	IS1713B (et)
LU (1)	LU91027I2 (et)
MY (1)	MY119778A (et)
NL (1)	NL300122I2 (et)
NO (2)	NO306117B1 (et)
NZ (1)	NZ274642A (et)
OA (1)	OA10575A (et)
PE (1)	PE15095A1 (et)
PL (1)	PL180002B1 (et)
RO (1)	RO117455B1 (et)
RU (1)	RU2140926C1 (et)
SA (1)	SA94150231B1 (et)
SG (1)	SG52650A1 (et)
SI (1)	SI0719278T1 (et)
SK (1)	SK281869B6 (et)
TW (1)	TW369521B (et)
WO (1)	WO1995007927A1 (et)
ZA (2)	ZA947118B (et)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2135167A1 (en) *	1992-05-20	1993-11-25	Donald W. Graham	New 17-ester, amide, and ketone derivatives of 3-oxo-4- azasteroids as 5a-reductase inhibitors
DE69329933T2 (de) *	1992-10-06	2001-07-19	Merck & Co., Inc.	17-beta-carboxanilid derivate von 4-aza-5-alpha-androstan-3-one als 5-alpha-reduktase-hemmende arzneimittel
TW408127B (en) *	1993-09-17	2000-10-11	Glaxo Inc	Androstenones
TW382595B (en) *	1993-10-15	2000-02-21	Merck & Co Inc	Pharmaceutical composition for use in arresting and reversing androgenic alopecia
US5547957A (en)	1993-10-15	1996-08-20	Merck & Co., Inc.	Method of treating androgenic alopecia with 5-α reductase inhibitors
ZA948285B (en) *	1993-10-21	1995-06-19	Merck & Co Inc	16-Substituted-4-aza-androstane 5-alpha-reductase isozyme 1 inhibitors
US5817818A (en) *	1994-09-16	1998-10-06	Glaxo Wellcome Inc.	Androstenones
USRE39056E1 (en) *	1995-09-15	2006-04-04	Merck & Co, Inc.	4-Azasteroids for treatment of hyperandrogenic conditions
US5872126A (en) *	1996-09-06	1999-02-16	Merck & Co., Inc.	Methods and compositions for treating preterm labor
US5935968A (en) *	1997-03-17	1999-08-10	Merck & Co., Inc.	Methods for treating polycystic ovary syndrome
GB9717428D0 (en) *	1997-08-19	1997-10-22	Glaxo Group Ltd	Pharmaceutical composition
WO1999021563A1 (en) *	1997-10-28	1999-05-06	Merck & Co., Inc.	Prevention of precipitated acute urinary retention
EP1094798A2 (en) *	1998-03-11	2001-05-02	Endorecherche Inc.	INHIBITORS OF TYPE 5 AND TYPE 3 17beta-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE
EP1321146A3 (en) *	1998-03-11	2004-06-02	Endorecherche Inc.	Inhibitors of type 5 and 3 17beta-hydroxysteroid dehydrogenase and methods for their use
US5998427A (en) *	1998-05-14	1999-12-07	Glaxo Wellcome Inc.	Androstenones
AU4701299A (en) *	1998-06-23	2000-01-10	Stuart R. Adler	Therapeutic applications of estrogenic carboxylic acids
AU2512800A (en) *	1999-02-03	2000-08-25	Eli Lilly And Company	Alpha1-adrenergic receptor antagonists
DE60021720T2 (de)	1999-05-04	2006-06-01	Strakan International Ltd.	Androgen glykoside und die androgenische aktivität davon
US6645974B2 (en)	2001-07-31	2003-11-11	Merck & Co., Inc.	Androgen receptor modulators and methods for use thereof
AU2002331916B2 (en) *	2001-10-03	2008-07-24	Merck Sharp & Dohme Corp.	Androstane 17-beta-carboxamides as androgen receptor modulators
WO2003062187A1 (en) *	2002-01-25	2003-07-31	Asahi Glass Company, Limited	Process for producing 2,5-bis(trifluoromethyl)nitrobenzene
EP1743656A3 (en)	2002-04-24	2007-03-07	Boehringer Ingelheim Pharma GmbH & Co. KG	Pharmaceutical combination for the treatment of benign prostatic hyperplasia or for the long-term prevention of acute urinary retention
EP1501512A4 (en) *	2002-04-30	2009-11-18	Merck & Co Inc	4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS
US7326717B2 (en) *	2003-05-06	2008-02-05	L'oreal	Pyrimidine n-oxide compounds for stimulating the growth of keratin fibers and/or reducing loss thereof
US7022854B2 (en) *	2003-07-17	2006-04-04	Dr. Reddy's Laboratories, Limited	Forms of dutasteride and methods for preparation thereof
US20050059692A1 (en) *	2003-09-09	2005-03-17	Dr. Reddy's Laboratories Limited	Process for the preparation of 17beta-N-[2,5-bis(trifluoromethyl)phenyl] carbamoyl-4-aza-5-alpha-androst-1-en-3-one
EP1746998A1 (en) *	2004-03-22	2007-01-31	Ranbaxy Laboratories, Ltd.	Combination therapy for lower urinary tract symptoms
EP1734963A4 (en)	2004-04-02	2008-06-18	Merck & Co Inc	METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
CN101005841A (zh) *	2004-08-25	2007-07-25	默克公司	雄激素受体调节剂
EP1824495A2 (en) *	2004-12-03	2007-08-29	ProteoSys AG	Finasteride, dutasteride and related compounds for preventing/treating neurologically-associated disorders
US20060193804A1 (en) *	2005-02-24	2006-08-31	L'oreal	Haircare use of cyclic amine derivatives
AU2006229840B2 (en)	2005-03-25	2010-12-23	Merck Sharp & Dohme Corp.	Method of treating men with testosterone supplement and 5alpha-reductase inhibitor
WO2007120263A2 (en) *	2005-11-10	2007-10-25	Dr. Reddy's Laboratories Ltd.	Preparation of dutasteride
EP1897533A1 (en) *	2006-09-08	2008-03-12	Revotar Biopharmaceuticals AG	Use of 1,6-Bis [3-(3-carboxymethylphenyl)-4-(2-alpha -D-mannopyranosyl-oxy)-phenyl] hexane for the preparation of cosmetic compositions
EP1946756A1 (en) *	2007-01-17	2008-07-23	Revotar Biopharmaceuticals AG	Use of entacapone in cosmetic, dermatological and pharmaceutical compositions
FR2920309B1 (fr)	2007-08-28	2010-05-28	Galderma Res & Dev	Utilisation de travoprost pour traiter la chute des cheveux
US20090076057A1 (en) *	2007-09-13	2009-03-19	Protia, Llc	Deuterium-enriched dutasteride
EP2050436A1 (en)	2007-12-21	2009-04-22	Siegfried Generics International AG	Pharmaceutical composition containing dutasteride
AR070313A1 (es) *	2008-01-03	2010-03-31	Gador Sa	Un procedimiento para preparar una forma solida y cristalina de dutasteride, una forma polimorfica del compuesto (forma iii) y una composicion farmaceutica que incluye dicha forma
FR2929118B1 (fr)	2008-03-28	2010-05-07	Oreal	Utilisation de l'association de madecassoside et/ou de terminoloside et d'une arginine pour induire et/ou stimuler la croissance de ces fibres keratiniques humaines et/ou freiner leur chute
FR2929117B1 (fr)	2008-03-28	2010-05-07	Oreal	Utilisation de l'association du 2,4-diaminopyrimidine 3-n-oxyde et du madecassosside et/ou du terminoloside pour induire et/ou stimuler la croissance de ces fibres keratiniques humaines et/ou freiner leur chute
HUE028337T2 (en)	2008-04-03	2016-12-28	Neurmedix Inc	Shapes of a drug in a solid state
US20100048598A1 (en) *	2008-08-21	2010-02-25	Sateesh Kandavilli	Topical compositions comprising 5-alpha reductase inhibitors
CN101759762B (zh) *	2008-11-06	2013-03-20	天津金耀集团有限公司	4ad在制备度他雄胺中的应用
WO2011004242A2 (en) *	2009-07-09	2011-01-13	Aurobindo Pharma Limited	An improved process for the preparation of dutasteride
FR2949052B1 (fr)	2009-08-13	2015-03-27	Oreal	Procede de traitement cosmetique du cuir chevelu.
EP2468262A1 (en)	2010-12-06	2012-06-27	Krka Tovarna Zdravil, D.D., Novo Mesto	Pharmaceutical composition comprising dutasteride
WO2012162776A1 (pt) *	2011-06-03	2012-12-06	Eurofarma Laboratórios S.A	Composição farmacêutica para o tratamento de hiperplasia prostática benigna
HU230730B1 (hu)	2011-06-30	2017-12-28	Richter Gedeon Nyrt	Eljárás (5alfa,17béta)-N-[2,5-bisz-(trifluormetil)-fenil]-3-oxo-4-aza-5-androszt-1-én-17-karbonsavamid előállítására
CN103059098B (zh) *	2011-10-24	2015-04-01	成都国为医药科技有限公司	一种度他雄胺的制备方法
US9622981B2 (en)	2011-11-17	2017-04-18	Mylan Inc.	Liquid-filled hard gel capsule pharmaceutical formulations
CN102382165B (zh) *	2011-12-02	2014-05-07	华润赛科药业有限责任公司	一种度他雄胺的制备方法
CN103554210A (zh) *	2012-01-05	2014-02-05	中国药科大学	甾体类5α-还原酶抑制剂、其制备方法及其医药用途
CN102532236B (zh) *	2012-01-05	2014-04-16	中国药科大学	甾体类5α-还原酶抑制剂、其制备方法及其医药用途
KR101976137B1 (ko)	2012-01-25	2019-05-09	한미약품 주식회사	두타스테라이드 함유 자가 유화 약물전달 시스템용 조성물 및 이의 제조 방법
CA2870666A1 (en)	2012-04-16	2013-10-24	Case Western Reserve University	Compositions and methods of modulating 15-pgdh activity
WO2014002015A1 (en)	2012-06-25	2014-01-03	Ranbaxy Laboratories Limited	Pharmaceutical composition comprising dutasteride
US20160022606A1 (en) *	2013-03-14	2016-01-28	Pellficure Pharmaceuticals Inc.	Novel therapy for prostate carcinoma
CN103254268A (zh) *	2013-05-16	2013-08-21	寿光市富康化学工业有限公司	一种制备度他雄胺的工艺
BR102013020508B1 (pt)	2013-08-12	2021-01-12	Ems S/A.	Forma de dosagem que compreende um inibidor de esteroide 5-alfa-redutase e um bloqueador alfa, processo para a preparaçãode uma forma de dosagem e uso da forma de dosagem
CA2927730A1 (en)	2013-10-15	2015-05-07	Case Western Reserve University	Compositions and methods of modulating short-chain dehydrogenase activity
ES2555485T1 (es)	2014-05-26	2016-01-04	Galenicum Health S.L.	Composiciones farmacéuticas que contienen un agente activo
EP3226859B1 (en)	2014-12-05	2025-03-26	Case Western Reserve University	Akr1a1 inhibitors for use in lowering cholesterol and modulate s-nitrosylation
KR101590072B1 (ko)	2014-12-23	2016-01-29	한미약품 주식회사	두타스테라이드를 포함하는 자가유화 약물전달 시스템용 조성물
EP3653300A1 (en) *	2015-03-13	2020-05-20	Dow Global Technologies LLC	Olefin oligomerization process with a catalyst comprising a chromium complex with a phosphacycle-containing ligand
KR102503428B1 (ko)	2015-12-22	2023-02-24	한미약품 주식회사	두타스테라이드를 포함하는 경구용 연질 캡슐 제형용 포장재
KR101968754B1 (ko)	2016-03-16	2019-04-12	한미약품 주식회사	두타스테라이드 및 탐수로신 함유 경질 캡슐 복합제 및 그 제조방법
KR101716878B1 (ko)	2016-05-12	2017-03-15	주식회사 유유제약	글리세롤 지방산에스테르유도체 또는 프로필렌글리콜 지방산에스테르유도체를 함유한 두타스테리드와 타다라필의 복합 캡슐제제 조성물 및 이의 제조방법
EP3548035A4 (en)	2016-11-30	2020-07-22	Case Western Reserve University	COMBINATIONS OF 15-PGDH INHIBITORS WITH CORCOSTEROIDS AND / OR TNF INHIBITORS AND THEIR USES
US11718589B2 (en)	2017-02-06	2023-08-08	Case Western Reserve University	Compositions and methods of modulating short-chain dehydrogenase
WO2019045501A1 (ko)	2017-09-01	2019-03-07	제이더블유중외제약 주식회사	두타스테라이드를 포함하는 고형 제제 및 이의 제조방법
KR101996597B1 (ko)	2017-10-13	2019-07-31	주식회사 유유제약	두타스테리드와 타다라필을 용해시킨 경구용 캡슐 제형의 복합제제
WO2019225924A1 (ko) *	2018-05-21	2019-11-28	(주)인벤티지랩	두타스테라이드를 포함하는 마이크로 입자 및 이의 제조 방법
KR102281252B1 (ko)	2018-05-21	2021-07-23	(주)인벤티지랩	두타스테라이드를 포함하는 마이크로 입자 및 이의 제조 방법
CN113507931B (zh)	2018-11-21	2025-05-27	卡斯西部储备大学	调节短链脱氢酶活性的组合物和方法
KR20200074759A (ko)	2018-12-17	2020-06-25	동국제약 주식회사	두타스테라이드를 함유하는 고형제제
IL298043A (en)	2020-05-20	2023-01-01	Rodeo Therapeutics Corp	Compositions and methods of modulating short-chain dehydrogenase activity
WO2024144084A1 (ko) *	2022-12-26	2024-07-04	주식회사 유영제약	주 1회 투여를 위한 정제 형태의 고함량 두타스테리드 약제학적 조성물 및 이의 제조방법

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4377584A (en) *	1978-04-13	1983-03-22	Merck & Co., Inc.	4-Aza-17β-substituted-5α-androstan-3-one-reductase inhibitors
AU527030B2 (en) *	1978-04-13	1983-02-10	Merck & Co., Inc.	4-aza-17-substituted-5a-androstan-3-ones
US4191759A (en) *	1978-04-13	1980-03-04	Merck & Co., Inc.	N-substituted-17β-carbamoylandrost-4-en-3-one 5α reductase inhibitors
US4220775A (en) *	1979-03-15	1980-09-02	Merck & Co., Inc.	Preparation of 4-aza-17-substituted-5α-androstan-3-ones useful as 5α-reductase inhibitors
US4317817A (en) *	1979-08-27	1982-03-02	Richardson-Merrell Inc.	Novel steroid 5α-reductase inhibitors
DK465481A (da) *	1980-11-21	1982-05-22	Hoffmann La Roche	Fremgangsmaade til fremstilling af d-homostemoider
US5049562A (en) *	1984-02-27	1991-09-17	Merck & Co., Inc.	17β-acyl-4-aza-5α-androst-1-ene-3-ones as 5α-reductase inhibitors
ATE67503T1 (de) *	1984-02-27	1991-10-15	Merck & Co Inc	17-beta-substituierte-4-aza-5-alpha-androstenon und ihre anwendung als 5-alpha-reduktaseinhibitoren.
NZ211145A (en) *	1984-02-27	1988-10-28	Merck & Co Inc	4-aza-5-alpha-androst-1-en-3-ones and pharmaceutical compositions
US4760071A (en) *	1984-02-27	1988-07-26	Merck & Co., Inc.	17β-N-monosubstituted carbamoyl-4-aza-5α-androst-1-en-3-ones which are active as testosterone 5α-reductase inhibitors
GB8505862D0 (en) *	1985-03-07	1985-04-11	Erba Farmitalia	Steroidic 5alpha-reductase inhibitors
DE3780778T2 (de) *	1986-11-20	1993-01-14	Merck & Co Inc	Topisches arzneimittel enthaltend 17-beta-methoxy-carbonyl-4-methyl-4-aza-5-alpha-androst-1-en-3-one.
US4845104A (en) *	1986-11-20	1989-07-04	Merck & Co., Inc.	Oxidized analogs of 17β-N-monosubstituted-carbamoyl-4-aza-5-α-androstan-3-ones
US4888336A (en) *	1987-01-28	1989-12-19	Smithkline Beckman Corporation	Steroid 5-alpha-reductase inhibitors
US5110939A (en) *	1987-01-28	1992-05-05	Smithkline Beecham Corporation	Intermediates in the preparation of steriod 5-alpha-reductase inhibitors
US4814324A (en) *	1987-03-06	1989-03-21	Merck & Co., Inc.	Sterol inhibitors of testosterone 5α-reductase
DE3888378T2 (de) *	1987-04-03	1994-09-29	Merck & Co Inc	Behandlung von Prostatacarcinoma mit 17-beta-n-monosubstituierten-Carbamoyl-4-aza-5-alpha-Androst-1-en-3-onen.
DE3888994T2 (de) *	1987-04-03	1994-11-03	Merck & Co Inc	Behandlung von androgener Alopecia mit 17-beta-n-mono-substituierten-carbamoyl-4-aza-5-alpha-androst-1-en-3-onen.
US4910226A (en) *	1987-04-29	1990-03-20	Smithkline Beckman Corporation	Steroid 5-alpha-reductase inhibitors
US5041433A (en) *	1987-04-29	1991-08-20	Smithkline Beecham Corporation	11-keto or hydroxy 3,5-diene steroids as inhibitors of steriod 5-α-reductase
ZA883034B (en) *	1987-04-29	1989-03-29	Smithkline Beckman Corp	Steroid 5-alpha-reductase inhibitors
NZ225100A (en) *	1987-06-29	1991-09-25	Merck & Co Inc	Reaction of steroids (including 4-azasteroids) with a silylating agent in the presence of a quinone to introduce a delta' double bond and silylated intermediates
US4954446A (en) *	1988-05-25	1990-09-04	Smithkline Beecham Corporation	Aromatic steroid 5-α-reductase inhibitors
AU627466B2 (en) *	1988-05-25	1992-08-27	Smithkline Beckman Corporation	Aromatic steroid 5-alpha-reductase inhibitors
US5237061A (en) *	1988-10-31	1993-08-17	Merck & Co., Inc.	Methods of synthesizing benign prostatic hypertropic agents and their intermediates
US4937237A (en) *	1988-12-23	1990-06-26	Smithkline Beckman Corporation	Phosphinic acid substituted aromatic steroids as inhibitors of steroid 5-60 -reductase
US4970205A (en) *	1988-12-23	1990-11-13	Smithkline Beecham Corporation	Sulfonic acid substituted aromatic steroids as inhibitors of steroid 5-α-reductase
US4882319A (en) *	1988-12-23	1989-11-21	Smithkline Beckman Corporation	Phosphonic acid substituted aromatic steroids as inhibitors of steroid 5-α-reductase
US5026882A (en) *	1988-12-23	1991-06-25	Smithkline Beecham Corporation	Phosphinic acid substituted steroids as inhibitors of steroid 5α-reductase
US4946834A (en) *	1988-12-23	1990-08-07	Smithkline Beecham Corporation	Phosphonic acid substituted steroids as steroid 5α-reductase inhibitors
US4966898A (en) *	1989-08-15	1990-10-30	Merrell Dow Pharmaceuticals Inc.	4-substituted 17β-(cyclopropylamino)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors
US4966897A (en) *	1989-08-15	1990-10-30	Merrell Dow Pharmaceuticals Inc.	4-substituted 17β-(cyclopropyloxy)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors
CA2023157A1 (en) *	1989-08-21	1991-02-22	Gary H. Rasmusson	17 beta-acyl-4-aza-5 alpha-androst-1-ene-3-ones as 5 alpha-reductase inhibitors
US5032586A (en) *	1989-08-24	1991-07-16	Smithkline Beecham Corporation	7-keto or hydroxy 3,5-diene steroids as inhibitors of steroid 5-alpha reductase
US5021575A (en) *	1989-11-13	1991-06-04	Merck & Co., Inc.	Method for introducing a 1,2 double bond into azasteroids
US5100917A (en) *	1989-12-29	1992-03-31	Merrell Dow Pharmaceuticals Inc.	Novel a-nor-steroid-3-carboxylic acid derivatives
GB9002922D0 (en) *	1990-02-09	1990-04-04	Erba Carlo Spa	17 beta-substituted-4-aza-5 alpha-androstan-3-one derivatives and process for their preparation
EP0462662A3 (en) *	1990-06-20	1992-08-19	Merck & Co. Inc.	17beta-n-monosubstituted adamantyl/norbornanyl carbamoyl-4-aza-5alpha-androst-1-en-3-ones and androstan-3-ones
US5061802A (en) *	1990-06-20	1991-10-29	Merck & Co. Inc.	17β-aminobenzoyl-4-aza-5α-androst-1-en-3-ones as benign prostatic hypertrophy agents
US5098908A (en) *	1990-06-20	1992-03-24	Merck & Co., Inc.	17β-hydroxybenzoyl-4-aza-5α-androst-1-en-3-ones as testosterone reductase inhibitors
EP0462664A3 (en) *	1990-06-20	1992-11-25	Merck & Co. Inc.	Specific 17beta-thiobenzoyl-4-aza-5alpha-androst-1-en-3-ones as antiandrogenic agents
EP0462665A3 (en) *	1990-06-20	1993-06-30	Merck & Co. Inc.	Selected 17beta-polyaroyl-4-aza-5alpha-androst-1-en-3-ones as steroidal reductase inhibitors
NZ239141A (en) *	1990-08-01	1994-04-27	Merrell Dow Pharma	4-amino-delta-4,6-steroids; preparatory processes and pharmaceutical compositions
US5318961A (en) *	1990-08-01	1994-06-07	Merrell Dow Pharmaceuticals Inc.	4-amino-Δ4-steroids and their use as 5α-reductase inhibitors
NZ239142A (en) *	1990-08-01	1994-05-26	Merrell Dow Pharma	4-amino-delta-4-steroids; preparatory processes and pharmaceutical compositions
US5091534A (en) *	1990-08-27	1992-02-25	Merck & Co., Inc.	Trialkylsilyl trifluoromethanesulfonate mediated α-methylenic carbon functionalization of 4-AZA-5α-androstan-3-one steroids
US5120847A (en) *	1990-08-27	1992-06-09	Merck & Co., Inc.	Process for iodinating or brominating the α-methylenic carbon of a secondary amide
US5061803A (en) *	1990-09-24	1991-10-29	Merck & Co., Inc.	Process for making 17-beta alkanoyl 3-oxo-4-aza-5-α-androst-1-enes
CA2050824A1 (en) *	1990-09-24	1992-03-25	John M. Williams	Process for making 3-oxo-4-aza-androst-1-ene 17-.beta.-ketones
US5061801A (en) *	1990-09-24	1991-10-29	Merck & Co., Inc.	Intermediate for making 3-oxo-4-aza-androst-1-ene 17β-ketones
IE76452B1 (en) *	1990-10-29	1997-10-22	Sankyo Co	Azasteroid compounds for the treatment of prostatic hypertrophy their preparation and use
NZ241979A (en) *	1991-03-20	1996-01-26	Merck & Co Inc	Treatment of benign prostatic hyperplasia using 5alpha-reductase inhibitor and an alpha1-adrenergic recepter blocker
IL101245A0 (en) *	1991-03-20	1992-11-15	Merck & Co Inc	Pharmaceutical compositions for the treatment of prostatic cancer
WO1992018132A1 (en) *	1991-04-17	1992-10-29	Merck & Co., Inc.	Pharmaceutical combination for the treatment of benign prostatic hyperplasia comtaining a 5 alpha-reductase inhibitor
GB9115676D0 (en) *	1991-07-19	1991-09-04	Erba Carlo Spa	Process for the preparation of 17 beta substituted-4-aza-5 alpha-androstan-3-one derivatives
US5304562A (en) *	1991-10-09	1994-04-19	Ciba-Geigy Corporation	17β-substituted Aza-androstane derivatives
JPH07502511A (ja) *	1991-12-20	1995-03-16	グラクソ、インコーポレーテッド	５‐α‐テストステロンレダクターゼ阻害剤
JP3164389B2 (ja) *	1991-12-25	2001-05-08	三共株式会社	４−アザステロイド類
WO1993023419A1 (en) *	1992-05-20	1993-11-25	Merck & Co., Inc.	NEW 7β-SUBSTITUTED-4-AZA-5α-CHOLESTAN-ONES AS 5α-REDUCTASE INHIBITORS
WO1993023038A1 (en) *	1992-05-20	1993-11-25	Merck & Co., Inc.	17-AMINO SUBSTITUTED 4-AZASTEROID 5α-REDUCTASE INHIBITORS
DE69329856D1 (de) *	1992-05-20	2001-02-15	Merck & Co Inc	Ester derivate von 4-aza-steroiden
ATE195129T1 (de) *	1992-05-20	2000-08-15	Merck & Co Inc	4-azasteroide als 5-alpha-reduktase
WO1993023039A1 (en) *	1992-05-20	1993-11-25	Merck & Co., Inc.	Substituted 4-aza-5a-androstan-ones as 5a-reductase inhibitors
WO1993023050A1 (en) *	1992-05-20	1993-11-25	Merck & Co., Inc.	NEW DELTA-17 AND DELTA-20 OLEFINIC AND SATURATED 17β-SUBSTITUTED-4-AZA-5α-ANDROSTAN-3-ONES AS 5α-REDUCTASE INHIBITORS
DE69329240D1 (de) *	1992-05-20	2000-09-21	Merck & Co Inc	17-ether und thioether von 4-aza-steroiden
CA2135167A1 (en) *	1992-05-20	1993-11-25	Donald W. Graham	New 17-ester, amide, and ketone derivatives of 3-oxo-4- azasteroids as 5a-reductase inhibitors
US5710275A (en) *	1992-05-20	1998-01-20	Merck & Co., Inc.	7β-substituted-4-aza-5α-androstan-3-ones as 5α-reductase inhibitors
TW239145B (et) *	1992-05-21	1995-01-21	Endorech Inc
GB9210880D0 (en) *	1992-05-21	1992-07-08	Smithkline Beecham Corp	Compounds
GB9216329D0 (en) *	1992-07-31	1992-09-16	Erba Carlo Spa	17beta-substituted 4-aza-5alpha-androstan-3-one derivatives
GB9216284D0 (en) *	1992-07-31	1992-09-16	Erba Carlo Spa	Fluorinated 17beta-substituted 4-aza-5alpha-androstane-3-one derivatives
HU212459B (en) *	1992-10-02	1996-06-28	Richter Gedeon Vegyeszet	Process for producing new 17-beta-substituted 4-aza-androstane-derivatives and pharmaceutical compositions containing them
DE69329933T2 (de) *	1992-10-06	2001-07-19	Merck & Co., Inc.	17-beta-carboxanilid derivate von 4-aza-5-alpha-androstan-3-one als 5-alpha-reduktase-hemmende arzneimittel
US5278159A (en) *	1992-10-06	1994-01-11	Merck & Co., Inc.	Aryl ester derivatives of 3-oxo-4-aza-androstane 17-β-carboxylates as 5-α-reductase inhibitors
IL107611A0 (en) *	1992-11-18	1994-02-27	Smithkline Beecham Corp	Steroid compounds and pharmaceutical compositions containing them
AP459A (en) *	1992-12-18	1996-02-14	Glaxo Wellcome Inc	Substituted 6-azaandrostenones.
US5380728A (en) *	1993-02-10	1995-01-10	Merck & Co., Inc.	Aldehyde metabolite of 17β-N-monosubstituted-carbamoyl-4-aza-5α-a
US5438061A (en) *	1993-07-16	1995-08-01	Merck & Co., Inc.	7-substituted-δ4-6-azasteroid derivatives as 5α-reductase inhibitors
TW408127B (en) *	1993-09-17	2000-10-11	Glaxo Inc	Androstenones

1994
- 1994-09-03 TW TW083108127A patent/TW369521B/zh active
- 1994-09-13 IS IS4205A patent/IS1713B/is unknown
- 1994-09-14 MY MYPI94002449A patent/MY119778A/en unknown
- 1994-09-15 ZA ZA947118A patent/ZA947118B/xx unknown
- 1994-09-15 AP APAP/P/1994/000669A patent/AP494A/en active
- 1994-09-15 ZA ZA947119A patent/ZA947119B/xx unknown
- 1994-09-15 PE PE1994250737A patent/PE15095A1/es not_active Application Discontinuation
- 1994-09-16 CZ CZ1996745A patent/CZ286069B6/cs not_active IP Right Cessation
- 1994-09-16 ES ES94929828T patent/ES2113127T3/es not_active Expired - Lifetime
- 1994-09-16 CA CA002170047A patent/CA2170047C/en not_active Expired - Lifetime
- 1994-09-16 CN CN94193410A patent/CN1057771C/zh not_active Expired - Lifetime
- 1994-09-16 WO PCT/US1994/010530 patent/WO1995007927A1/en not_active Ceased
- 1994-09-16 EP EP94929828A patent/EP0719278B1/en not_active Expired - Lifetime
- 1994-09-16 AT AT94929828T patent/ATE162199T1/de active
- 1994-09-16 RU RU96108410A patent/RU2140926C1/ru active
- 1994-09-16 DE DE69407978T patent/DE69407978T2/de not_active Expired - Lifetime
- 1994-09-16 NZ NZ274642A patent/NZ274642A/en not_active IP Right Cessation
- 1994-09-16 IL IL11097894A patent/IL110978A/en active Protection Beyond IP Right Term
- 1994-09-16 SK SK347-96A patent/SK281869B6/sk unknown
- 1994-09-16 PL PL94313492A patent/PL180002B1/pl unknown
- 1994-09-16 DE DE10399022C patent/DE10399022I2/de active Active
- 1994-09-16 CA CA002462061A patent/CA2462061A1/en not_active Abandoned
- 1994-09-16 DK DK94929828T patent/DK0719278T3/da active
- 1994-09-16 AU AU78751/94A patent/AU690925B2/en not_active Expired
- 1994-09-16 HU HU9600656A patent/HU220060B/hu unknown
- 1994-09-16 HK HK98103307A patent/HK1004334A1/en not_active IP Right Cessation
- 1994-09-16 RO RO96-00537A patent/RO117455B1/ro unknown
- 1994-09-16 KR KR1019960701363A patent/KR100364953B1/ko not_active Expired - Lifetime
- 1994-09-16 JP JP7509391A patent/JP2904310B2/ja not_active Expired - Lifetime
- 1994-09-16 SI SI9430130T patent/SI0719278T1/xx unknown
- 1994-09-16 HR HR940563A patent/HRP940563B1/xx not_active IP Right Cessation
- 1994-09-16 EE EE9600130A patent/EE03241B1/et unknown
- 1994-09-16 SG SG1996007353A patent/SG52650A1/en unknown
- 1994-10-10 SA SA94150231A patent/SA94150231B1/ar unknown
1995
- 1995-03-16 US US08/405,120 patent/US5565467A/en not_active Expired - Lifetime
1996
- 1996-03-08 BG BG100410A patent/BG62363B1/bg unknown
- 1996-03-13 OA OA60795A patent/OA10575A/en unknown
- 1996-03-15 NO NO961080A patent/NO306117B1/no not_active IP Right Cessation
- 1996-03-15 FI FI961231A patent/FI115216B/fi not_active IP Right Cessation
- 1996-08-22 US US08/708,167 patent/US5846976A/en not_active Expired - Lifetime
1997
- 1997-04-23 BR BR1100329-4A patent/BR1100329A/pt active IP Right Grant
1998
- 1998-02-12 GR GR980400317T patent/GR3026144T3/el unknown
2001
- 2001-01-03 CY CY0100002A patent/CY2219B1/xx unknown
2003
- 2003-03-07 NO NO2003003C patent/NO2003003I2/no unknown
- 2003-03-31 NL NL300122C patent/NL300122I2/nl unknown
- 2003-06-18 LU LU91027C patent/LU91027I2/fr unknown
2004
- 2004-07-26 CY CY200400002C patent/CY2004002I1/el unknown

Also Published As

Publication number	Publication date
BR1100329A (pt)	2000-06-13
CY2219B1 (en)	2003-04-18
PE15095A1 (es)	1995-06-04
BG62363B1 (bg)	1999-09-30
NO306117B1 (no)	1999-09-20
AP9400669A0 (en)	1994-10-31
NO961080L (no)	1996-03-15
SG52650A1 (en)	1998-09-28
IS1713B (is)	1998-12-30
HRP940563A2 (en)	1997-02-28
NZ274642A (en)	1997-11-24
RU2140926C1 (ru)	1999-11-10
IL110978A0 (en)	1994-11-28
AU690925B2 (en)	1998-05-07
FI115216B (fi)	2005-03-31
ATE162199T1 (de)	1998-01-15
DE10399022I2 (de)	2012-09-13
IS4205A (is)	1995-03-18
CA2170047C (en)	2004-11-09
NO961080D0 (no)	1996-03-15
NL300122I2 (nl)	2003-09-01
CZ74596A3 (en)	1996-09-11
ZA947119B (en)	1995-05-26
SA94150231B1 (ar)	2005-05-04
ES2113127T3 (es)	1998-04-16
SK34796A3 (en)	1996-07-03
RO117455B1 (ro)	2002-03-29
OA10575A (en)	2002-06-25
DK0719278T3 (da)	1998-09-14
CZ286069B6 (cs)	2000-01-12
AU7875194A (en)	1995-04-03
HUT73850A (en)	1996-09-30
HK1004334A1 (en)	1998-11-20
SI0719278T1 (sl)	1998-06-30
NL300122I1 (nl)	2003-06-02
PL313492A1 (en)	1996-07-08
LU91027I2 (fr)	2004-04-28
FI961231A0 (fi)	1996-03-15
FI961231L (fi)	1996-03-15
JPH09502731A (ja)	1997-03-18
AP494A (en)	1996-05-15
SK281869B6 (sk)	2001-08-06
HU220060B (hu)	2001-10-28
TW369521B (en)	1999-09-11
CA2170047A1 (en)	1995-03-23
HU9600656D0 (en)	1996-05-28
WO1995007927A1 (en)	1995-03-23
EP0719278A1 (en)	1996-07-03
CN1057771C (zh)	2000-10-25
MY119778A (en)	2005-07-29
CY2004002I2 (el)	2009-11-04
GR3026144T3 (en)	1998-05-29
HRP940563B1 (en)	2000-10-31
NO2003003I2 (no)	2007-06-11
IL110978A (en)	1999-01-26
US5565467A (en)	1996-10-15
CY2004002I1 (el)	2009-11-04
PL180002B1 (pl)	2000-11-30
DE69407978D1 (de)	1998-02-19
US5846976A (en)	1998-12-08
DE69407978T2 (de)	1998-05-07
CN1131424A (zh)	1996-09-18
JP2904310B2 (ja)	1999-06-14
EP0719278B1 (en)	1998-01-14
CA2462061A1 (en)	1995-03-23
KR100364953B1 (ko)	2003-04-08
DE10399022I1 (de)	2004-01-15
BG100410A (bg)	1996-09-30
ZA947118B (en)	1995-05-26

Publication	Publication Date	Title
EE03241B1 (et)	1999-12-15	Androstenooni derivaat 17ß-N-(2,5-bis(trifluorometüül))fenüülkarbamoüül-4-asa-5a-androst-1-een-3-oon ja selle farmatseutiliselt vastuvõetavad solvaadid
FI961809A7 (fi)	1996-05-20	Uudet (R)-5-karbamoyyli-8-fluori-3-N,N-disubstituoitu-amino 3,4-dihydr o-2H-1-bentsopyraanit
DE59410092D1 (de)	2002-05-08	Metallocenverbindung
FI953489A0 (fi)	1995-07-19	2,6-diaminopuriinijohdannaisia
FI944310A0 (fi)	1994-09-16	Heteroaryyliamino- ja heteroaryylisuolfonamidosubstituoituja 3-bentsyyliaminometyylipiperidiinejä ja vastaavia yhdisteitä
FI954651A7 (fi)	1995-09-29	Mahdollisesti substituoidut 6,8-kinoliinit
NO307254B1 (no)	2000-03-06	1,2,4-oksadiazolderivater og parasittbekjempningsmiddel inneholdende samme
PT1019358E (pt)	2003-09-30	3,3-diarilpropilaminas sua utilizacao e sua preparacao
ZA976222B (en)	1998-01-19	N-(4-aryl-thiazol-2-yl)-sulphonamide derivatives and their use.
DK0853617T3 (da)	2004-07-05	2,3-Dioxo-1,2,3,4-tetrahydro-quinoxalinylderivater
AU6636598A (en)	1998-10-20	Novel 3,4-dialkoxyphenyl derivatives and the use thereof
DE69431965D1 (de)	2003-02-06	Wirkstoff gegen fettsucht
AU7978794A (en)	1995-05-04	3,17-dihydroxy-3,7,16 and/or 17-methyl-androst-5-ene compounds, derivatives thereof, and their use
PT811593E (pt)	2002-11-29	Agentes insecticidas e acaricidas 1,4-diaril-2-fluor-2-buteno
HU9502863D0 (en)	1995-11-28	7-azabicyclo-[2.2.1]-heptane and -heptene derivatives as analgesics and anti-inflammatory agents
FI951252A7 (fi)	1995-04-18	10-substituoituja 1,8-dihydroksi-9(10H)antrakenonilääkeaineita
AU7075694A (en)	1995-01-24	Novel cross-linking agents and use thereof
AU6871696A (en)	1997-03-19	N-(1-isopropyl-2-methyl-1-propenyl)heteroaryloxyacetamides and the use thereof as herbicides
ITMI920870A1 (it)	1993-10-10	Poliestereimmide trmotropica, procedimento per la sua preparazione e suo impiego
BR9510289A (pt)	1997-11-11	Monômetros de ciclohexan-1-of 3,3-dissubstituido e compostos relacionados
NO306672B1 (no)	1999-12-06	N,N-dietyl-8,8-dipropyl-2-azaspiro[4,5]decan-2-propanamindimaleat, farmasöytisk blanding omfattende forbindelsen samt anvendelse derav
NO944024D0 (no)	1994-10-21	1,2-dihydro-2-okso-pyridin
KR950007960U (ko)	1995-04-15	회전의자
FI931050A0 (fi)	1993-03-09	Monitor
DK0707579T3 (da)	1999-09-13	Piperidinylsubstituerede methanoanthracener som D1/D2-antagonister og 5 HT2-serotanin-antagonister

Legal Events

Date	Code	Title	Description
2003-02-17	KB4A	Valid patent at the end of a year	Effective date: 20021231
2004-02-16	KB4A	Valid patent at the end of a year	Effective date: 20031231
2005-02-15	KB4A	Valid patent at the end of a year	Effective date: 20041231
2005-04-15	GB1A	Change in the ownership or in the address of the owner
2006-02-15	KB4A	Valid patent at the end of a year	Effective date: 20051231
2007-02-15	KB4A	Valid patent at the end of a year	Effective date: 20061231
2008-02-15	KB4A	Valid patent at the end of a year	Effective date: 20071231
2009-02-16	KB4A	Valid patent at the end of a year	Effective date: 20081231
2010-02-15	KB4A	Valid patent at the end of a year	Effective date: 20091231
2011-02-15	KB4A	Valid patent at the end of a year	Effective date: 20101231